Abstract
Background
Alzheimer’s disease (AD) and related dementias (ADRD) are common in older adults, their prevention and management are challenging problems. To prevent or delay ADRD, dietary supplements (DS) have emerged as a promising treatment; however, the role of DS usage on disease progression of patients with cognitive impairments remains unclear. Little clinical trial evidence is available, but substantial information is contained in electronic health records (EHR), including structured and unstructured data about patients’ DS usage and disease status. The objectives of this study were to (1) develop accurate natural language processing (NLP) methods to extract DS usage for patients with Mild Cognitive Impairment (MCI) and ADRD, (2) examine the coverage of DS in structured data versus unstructured data and (3) compare DS usage information in EHR with National Health and Nutrition Examination Survey (NHANES) data.
Methods
We collected EHR data for patients with MCI and ADRD. A pipeline to extract the usage information of DS from both structured data and unstructured clinical notes was developed in the study. For structured data, we used the medication table to identify the DS and for unstructured clinical notes, we applied Bidirectional Encoder Representations from Transformers (BERT) fine-tuning strategy to extract the DS usage status.
Results
The best named entity recognition model for DS achieved an F1-score of 0.964 and the PubMed BERT-based use status classifier had a weighted F1-score of 0.879. We applied these models to extract DS usage information from unstructured clinical notes and subsequently compared and combined with those from structured medication orders. In total, 125 unique DS were identified for patients with MCI and 108 unique DS were identified for patients with ADRD.
Conclusions
In this study, we developed an NLP-based pipeline to extract the DS use information from medication structured data and clinical notes in EHR for patients with MCI and ADRD. Our method could further help understand the DS usage of patients with MCI and ADRD, and how these DS could influence the diseases.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer




